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Abstract
Background: Mutations in the human ATRX gene cause developmental defects, including skeletal deformities and dwarfism.
ATRX encodes a chromatin remodeling protein, however the role of ATRX in skeletal development is currently unknown.
Methodology/Principal Findings: We induced Atrx deletion in mouse cartilage using the Cre-loxP system, with Cre
expression driven by the collagen II (Col2a1) promoter. Growth rate, body size and weight, and long bone length did not
differ in Atrx
Col2cre mice compared to control littermates. Histological analyses of the growth plate did not reveal any
differences between control and mutant mice. Expression patterns of Sox9, a transcription factor required for cartilage
morphogenesis, and p57, a marker of cell cycle arrest and hypertrophic chondrocyte differentiation, was unaffected.
However, loss of ATRX in cartilage led to a delay in the ossification of the hips in some mice. We also observed hindlimb
polydactily in one out of 61 mutants.
Conclusions/Significance: These findings indicate that ATRX is not directly required for development or growth of cartilage
in the mouse, suggesting that the short stature in ATR-X patients is caused by defects in cartilage-extrinsic mechanisms.
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Introduction
ATR-X syndrome (Alpha-Thalassemia/Mental Retardation,
X-linked) is a human disorder caused by mutations in the ATRX
gene[1,2]. Clinical manifestations include severe psychomotor and
mental retardation, characteristic facial features, urogenital
abnormalities, skeletal deformities and a-thalassemia [2]. Over
200 male ATR-X syndrome cases have been reported [3], and
female carriers are unaffected due to the skewed pattern of
X-inactivation [4]. ATR-X syndrome patients display a wide
range of skeletal abnormalities, and 66% of patients show
dwarfism [4]. About half of ATR-X patients have spinal
deformities such as kyphosis or scoliosis [2]. Delayed bone age is
characteristic of most cases studied by thorough radiological
investigation [2]. For some patients, these skeletal abnormalities
are apparent at birth, for others they manifest later in life, during
the pubertal growth spurt [4]. Other skeletal deformities
commonly seen in ATR-X patients include clinodactyly, brachy-
dactyly, tapering of the fingers, overlapping digits, and 40% of
patients have foot deformities [2]. A single case of bifid thumb has
been reported [4]. Despite a broad characterization of the variety
of physical and mental phenotypes, very few genotype/phenotype
correlations have been established, and none are associated with
the severity of skeletal deformities [5]. The molecular and genetic
basis of these phenotypes are therefore unknown and it is unclear if
these defects are due to a direct role of ATRX in the skeleton.
Global knockout of Atrx using a ubiquitous GATA-Cre system
leads to placental defects and embryonic lethality [6]. Conditional
ablation of ATRX in the forebrain causes p53-dependent
apoptotic cell death during embryogenesis, resulting in a smaller
brain at birth [7,8], while ATRX deficiency in the retina induces
specific loss of interneurons [9].
The ATRX protein contains a domain displaying high homology
to SNF2(SucroseNon-Fermenting 2)proteins,suggesting a role as a
chromatin remodeling protein [10]. The SNF family of proteins is
involved in transcriptional regulation, maintenance of chromosome
stability during mitosis and processing of DNA damage [11]. ATR-
X patient mutations are generally hypomorphic and do not cause
chromosomal instability[4]. However, depletion of ATRX in
mammalian cells leads to defects in chromosome cohesion and
mitotic progression [12]. In addition to its role during mitosis,
ATRX appears to be involved in the regulation of gene expression
[13].
The development of long bones occurs through endochondral
ossification, a highly regulated multi-step process initiated when
pluripotent mesenchymal cells aggregate to form the beginning of
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factors, such as Sox9, Sox5 and Sox6 [15,16], mesenchymal cells
differentiate into chondroblasts, which produce large quantities of
type II collagen (Col2) [17]. Chondroblasts mature to form
chondrocytes, which undergo rapid proliferation along the
longitudinal axis of the future bone, forming the cartilage growth
plate [18]. The differentiated chondrocytes in the center of the
cartilage model undergo hypertrophy, increasing in cell size and
secreting type X collagen (ColX) [19]. The hypertrophic
chondrocytes encased in calcified ECM secrete vascular endothe-
lial growth factor (VEGF), which recruits blood vessels bringing
osteoblasts and osteoclasts to form the primary ossification center;
and eventually undergo apoptosis [19]. Chondrocytes on either
end of this primary ossification center continue to proliferate, enter
hypertrophy and undergo apoptosis, thus allowing the bone to
grow longitudinally. Finally, woven bone is laid down in the area
of apoptotic chondrocytes and is remodeled by osteoblasts and
osteoclasts to form lamellar bone [20].
To examine whether skeletal defects in ATR-X patients could
be due to a requirement for ATRX in cartilage development, we
examined the outcome of cartilage-specific inactivation of ATRX
in mice, using the Cre-loxP system. Our findings demonstrate that
loss of ATRX specifically in chondrocytes induces minor skeletal
defects, but does not affect growth plate morphology and bone
growth.
Results
ATRX is expressed in chondrocytes
Expression of ATRX in chondrocytes was assessed using in vitro
and in vivo models. Immunohistochemistry of newborn (P0.5) and
three week-old wild type mice demonstrated that ATRX is
expressed throughout the cartilage growth plate. Strong nuclear
staining of ATRX was apparent in all cartilage cells, but was most
prominent in early hypertrophic chondrocytes. Lower levels of
staining were observed in terminally differentiated cells (Figure 1A).
Primary chondrocytes in monolayer culture were stained for
ATRX by immunofluorescence. In interphase, we observed a
punctate staining pattern within the nucleus that corresponded to
bodies stained intensely with DAPI (Figure 1B, left panel). Alpha-
tubulin (red) was used to visualize the location of the cytoplasm
and to identify microtubules during cell division. During
metaphase, ATRX was present exclusively at the edges of the
aligned chromosomes, similar to the localization at pericentro-
meric heterochromatin reported in other cell types (Figure 1B,
right panel) [12,21]. Western blots of primary cultured chondro-
cytes showed that full-length ATRX was expressed in cartilage
(Figure 2B).
Loss of ATRX in mouse chondrocytes does not affect
viability or growth
We utilized the Cre-LoxP system to generate mice with
cartilage-specific inactivation of the Atrx gene. Female mice
previously engineered with loxP sites flanking exon 18 of Atrx [7]
were mated with male mice expressing Cre recombinase under the
control of the mouse collagen II (Col2a1) promoter [22]. Reverse
transcriptase PCR (RT-PCR) analysis of ATRX transcripts in
cultured primary chondrocytes confirmed a strong reduction in
wild type Atrx mRNA and the presence of low levels of a shorter
transcript resulting from the recombination event in mutant
cartilage (Figure 2A). These results confirm previous reports that
the mRNA species generated by the recombination event is
unstable [6,7]. Levels of ATRX protein in chondrocytes from ribs
of newborn mice were assessed by immunoblotting. ATRX
protein amounts were substantially decreased in Atrx
Col2cre
chondrocytes (Figure 2B). In contrast, ATRX protein levels in
brain and bone (calvariae) were unchanged in mutant mice,
validating the tissue specific activity of the Col2a1 Cre (Figure 2B).
Loss of ATRX protein was further confirmed by immunofluores-
cence of cultured chondrocytes isolated from Atrx
Col2Cre and control
littermate mice (Figure 2C) and by immunohistochemistry of
Atrx
Col2Cre and control growth plates (Figure 2D). These data
showed that our breeding scheme resulted in specific and efficient
loss of ATRX protein in cartilage.
Atrx
Col2Cre mice were obtained at expected Mendelian ratios,
indicating that loss of ATRX in cartilage does not result in
embryonic or neonatal lethality (59 control males, 61 KO males
out of 29 litters). In addition, Atrx
Col2Cre mice showed no significant
difference in growth when weighed daily from birth to weaning
and again at one year of age (Figure 3A), or in body length at three
weeks of age compared to wild-type littermates (Ctrl: 6.30 cm
STD: 0.21, KO: 6.17 cm STD: 0.38, p.0.05). Body length at 6
and 12 months was also unaffected (data not shown). Null males
were capable of mating and producing offspring when backcrossed
to floxed females to produce second-generation tissue-specific
knockout mice.
Skeletal preparations from newborn and weanling (21 day old)
mice showed no change in skeletal morphology, bone length or
extent of ossification, as determined by the ratio of Alizarin red to
Figure 1. Expression and localization of ATRX in growth plate
chondrocytes. (A) Immunostaining of ATRX in humerus growth plates
of P0.5 and P21 mice. ATRX is seen in the nuclei of resting, proliferating
and early hypertrophic cells in the growth plates (arrows). Scale bar: 100
mm. Regions of the growth plate are identified as resting (red arrow),
proliferating (yellow), hypertrophic (green) and mineralized (blue). (B)
Immunofluorescence detection of ATRX in primary mouse chondro-
cytes isolated from E15.5 long bones. Merged image of ATRX (green),
DAPI (blue) and alpha-tubulin (red) reveals a punctate ATRX staining
pattern restricted to the nucleus during interphase (left panel) and
specific localization to condensed chromatin during mitosis (right
panel). Scale bar: 10 mm.
doi:10.1371/journal.pone.0007106.g001
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tibia, femur, radius, ulna, and humerus were measured, as well as
the length and width of the skulls. Average measurements obtained
from four independent littermate pairs revealed no significant
changes in the length of long bone elements between control and
mutant mice (Figure 3D).
Growth plate morphology is not affected by the loss of
ATRX
Histochemical staining was conducted on paraffin sections of
the growth plates of Atrx
Col2Cre and control mice to examine
proportions of resting, proliferative and hypertrophic zones. No
difference in growth plate architecture or chondrocyte morphol-
ogy was detected between genotypes at P0.5 or P21 (Figure 4A). In
agreement with these data, no significant differences were seen in
the length of any growth plate zone in three independent litters
(Figure 4B). The early chondrogenic marker Sox9 was expressed
in resting and proliferating chondrocytes of control and KO
sections, demonstrating that loss of ATRX in growth plates had no
effect on Sox9 expression (Figure 4C). To confirm that
differentiation was unaffected in mutant chondrocytes, long bone
sections were stained for p57, a cyclin-dependent protein kinase
inhibitor that is expressed by prehypertrophic, postmitotic
chondrocytes [23]. The pattern of p57-positive cells in the mutant
growth plates at P0.5 and P21 (Figure 4D) was not different
between control and mutant mice, suggesting that loss of ATRX in
the cartilage growth plate does not affect terminal differentiation
of chondrocytes. In addition, the expression of other cartilage
markers such as ColX, Col2, or aggrecan was not altered at P0.5
or at P21 (data not shown), indicating that chondrocyte
differentiation was unaffected by loss of ATRX expression in
cartilage.
Conditional loss of ATRX in the mouse skeleton causes
minor ossification defects
Although no overall changes in skeletal size or proportions were
seen in the Atrx
Col2Cre mice, minor delays in development were seen
in some mice. Half (2/4) of the mutants examined by skeletal
staining at day 21 displayed a delay in ossification of the union
between the pubis and the ischium (Figure 5A). In those mutant
mice where ossification was complete by day 21, the site of union
was uneven with a spur-like bone projection. Both phenotypes
suggest a mild defect in the ossification of the hip in the Atrx
Col2Cre
mice.
Figure 2. Levels of ATRX are decreased in the cartilage of Atrx
Col2Cre mice. (A) RT-PCR analysis of RNA isolated from newborn rib cartilage (Cr)
or brain (Br) from Atrx
Col2Cre males (KO) and control littermates (Ctrl). Amplification was performed with primers flanking the loxP sites, in introns 17
and 20. The expected amplicon of 394 bp was obtained in control and an additional amplicon of 254 bp was obtained in KO cartilage caused by the
recombination event. The levels of the recombined product are low, as described previously [6,7], suggesting that this product is unstable. (B)
Immunoblotting for Atrx from proteins isolated from newborn control and KO rib chondrocytes, calvariae and brain tissue. Atrx expression is greatly
reduced in KO chondrocytes, but unaffected in calvariae and brain of KO animals. Beta-actin was used as a loading control. (C) Immunofluorescence
detection of ATRX in control and Atrx
Col2Cre primary chondrocytes isolated from newborn long bones shows the loss of ATRX protein in KO
chondrocytes. Scale bar: 10 mm. (D) Immunohistochemistry on growth plates from P0.5 and P21 mice. ATRX staining is reduced in KO growth plates.
Scale bar: 100 mm.
doi:10.1371/journal.pone.0007106.g002
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Col2Cremales
was an extra digit in a hind foot (Figure 5B). This digit resembled
an additional digit, similar to the fourth digit, rather than a
bifurcation of the fifth toe. The toe appeared normal, and in
skeletal preparations showed no gross differences from other digits.
Discussion
In this study, we show that loss of the ATRX protein specifically
in cartilage of mice does not cause a major defect in skeletal
growth or development. Although ATRX loss in the cartilage of
mice was confirmed by immunohistochemistry, immunofluores-
cence and western blot analyses, we show that long bones from
Atrx
Col2Cre mice do not differ from controls in length or growth-
plate morphology, and that these mice achieve the same adult
length and weight as control littermates. Furthermore, mutant
mice are viable and breed normally, with no defects seen in
second-generation knockouts.
Whole skeletal stains for ossified bone and cartilage were used to
characterize the entire skeleton of Atrx
Col2Cre mice. Qualitative and
quantitative study of the control and Atrx
Col2Cre skeletons showed no
overall changes in cartilage proportions and lengths of individual
elements.
The minor defects observed in our mouse model suggest a mild
effect from ATRX deficiency that may manifest only occasionally.
This is not unexpected, as the limb and digit phenotypes observed
in ATR-X syndrome patients are also highly variable. In a study of
sixty-five unrelated patients, one case of bifid thumb was observed
[5]. The varied hand and foot deformities in some ATR-X
patients suggest that the effect on limb development may differ
between individuals, even those with identical mutations [5].
Thorough radiologic investigations of ATR-X patients have
shown that the most common phenotypic abnormalities were
delayed bone age and coxa valga [24]. The delay in hip
ossification seen in our mice may be due to a similar delay in
bone age.
Previous studies have shown that loss of ATRX in other tissues
in the mouse causes severe and fatal defects [6,7,9]. Loss of ATRX
in the mouse forebrain has been shown to result in widespread
hypocellularity in the hippocampus and neocortex, as well as an
overall reduction in forebrain size. These mice exhibit reduced
weight and perinatal lethality, demonstrating the importance of
ATRX in the brain [7]. Similarly, loss of ATRX in the 16-cell
morula stage has revealed a specific and essential role for ATRX
in the formation of the extraembryonic trophoblast in mice.
Figure 3. Effects of ATRX loss-of-function on growth and development of the skeleton. (A) Weight measurements from control and KO
mice. No differences were seen in the growth of Atrx
Col2Cre mice compared to control littermates, and weight gain was normal at all stages of
development. (B, C) Skeletal stains of newborn and p21 control and KO mice showing cartilage (blue) and bone (red) proportions. Extent of limb
ossification and skeletal proportions between control and mutant pups were unaffected at birth and at three weeks (D) Long bone lengths and skull
proportions were measured from four control/KO littermate pairs at p21, and found to be unaffected by ATRX loss.
doi:10.1371/journal.pone.0007106.g003
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early embryonic death at E9.5[6]. A third model examining the
role of ATRX in the developing retina showed that ATRX loss-of-
function leads to loss of interneurons, specifically, amacrine and
horizontal cells. These mice demonstrated a defect in interneuron
differentiation and survival, which is associated with functional
deficits that may be similar to the subset of ATR-X patients with
visual anomalies [9].
This is the first study examining the specific loss of ATRX in the
skeletal system, and surprisingly we observed only minor abnor-
malities. Since these effects are much less severethan in all other cell
types examined, despite marked expression of ATRX in wild type
chondrocytes, our data suggest cell type-specific requirement for
ATRX function in cell survival and differentiation.
One assumption in our model is that destabilization and
subsequent breakdown of the Atrx mRNA is an accurate model of
the hypomorphic gene expression seen in ATRX patients. While
our model deletes only the long isoform of ATRX and retains the
short isoform (ATRXt), it is unlikely that ATRXt has equivalent
functions to the full length protein, as it lacks the functional SWI/
SNF domain [25]. In addition, the same floxed Atrx mouse line has
been used by us and others to successfully conduct loss of function
studies in other organs, such as the brain [7,8] or eye [9]. Since
loss of ATRX does not affect cartilage development in mice, it
seems likely that the skeletal defects in ATR-X patients are not due
to direct effects of the mutant proteins in chondrocytes.
We have used the cartilage-specific collagen II promoter, which
is activated around embryonic day 9, for inactivation of the Atrx
gene. However, there remains a possibility that some of the limb
phenotypes seen in ATR-X patients (e.g. patterning defects
affecting the digits) are due to an earlier effect, such as a function
Figure 4. ATRX-null growth plates are indistinguishable from
controls. (A) Growth plate sections from control and Atrx
Col2Cre mice at
P0.5 and P21 were stained with safranin-O/Fast green, demonstrating
unaltered growth plate architecture and morphology in mutant mice.
Scale bar: 100 mm. (B) No significant difference in the length of the
resting, proliferating or hypertrophic zones could be detected between
genotypes at birth or weaning (N=3 littermate pairs; two-tailed T-test).
Error bars depict standard error of the mean (SEM). (C) Expression of
Sox9, an early chondrocyte differentiation marker expressed in resting
and proliferating chondrocytes, is not altered in the absence of ATRX at
P0.5 or P21. Scale bar: 50 mm. (D) Immunohistochemistry for the
differentiation marker p57 reveals that ATRX loss has no effect on the
proportion of chondrocytes reaching terminal differentiation. Scale bar:
100 mm.
doi:10.1371/journal.pone.0007106.g004
Figure 5. Minor defects observed in Atrx
Col2Cre mice. (A) Pelvis
phenotype of P21 control and Atrx
Col2Cre mice. Arrows indicate the site
of delayed ossification in mutant mice. (B) Hind limb of mutant mouse
with one additional digit, before and after skeletal preparation to stain
for cartilage (blue) and bone (red). The additional digit is indicated by
an arrow.
doi:10.1371/journal.pone.0007106.g005
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initial mesenchymal cell template. Since loss of ATRX occurs later
in development in our model, we cannot rule out such an earlier
function for the protein. Use of an early limb bud-specific
promoter, such as the Prx1 limb enhancer [26], to direct Atrx
inactivation could answer this outstanding question. Additionally,
a later deficiency may also contribute to the observed patient
skeletal abnormalities. For example, defects in osteoblasts could
contribute to delayed bone age seen in patients or reduced overall
growth. Atrx deletion specifically in osteoblasts could be induced by
using the a1(I)-collagen promoter to drive cre expression [27].
These experiments have been initiated in our laboratory.
An alternative explanation for the surprising lack of skeletal
defects in our mice is that the skeletal defects observed in patients
might be secondary to abnormalities in other organs, such as
neuroendocrine defects stemming from ATRX dysfunction in the
nervous system [28]. There is much new evidence demonstrating
that bone growth can be regulated centrally via cytokines,
hormones and transcription factors, including the hormone leptin
[29]. Experiments using leptin directly on bone cells have shown
no effect on bone remodeling, however intracerebroventricular
leptin infusion into leptin-deficient mice leads to an effect on bone
mass via the nervous system [29]. Similarly, hematopoietic systems
within the bone marrow have been shown to be influenced by the
neurohormone melanin and catecholamines [30]. Both factors also
have hematopoietic roles, and are present in substantial amounts
in the bone marrow, supporting the idea that neural and
neuroendocrine factors have a direct effect on the bone
microenvironment. Together, these studies suggest that cell defects
in the hypothalamus (in the case of leptin) or the pineal gland (in
the case of melatonin) may have a central influence on the
development and homeostasis of the skeleton.
Importantly, it appears likely that the large variety of skeletal
and growth abnormalities in ATRX patients does not have one
common cellular origin; instead it appears that some defects (e.g.
digit malformations) could be due to alterations in the early
patterning of the limb, others (such as delayed bone age) could be
caused by defects in osteoblasts (or possibly osteoclasts) and a third
group (such as growth retardation) could be caused by abnormal
neuroendocrine signaling. These possibilities will require exami-
nation as alternative mechanisms for the pathogenesis of ATR-X
syndrome.
Materials and Methods
Histology and immunohistochemistry
Histology and immunohistochemistry procedures were per-
formed as described [32] with minor modifications. Sections were
incubated in 3% H2O2 for 15 min at room temperature, followed
by boiling for 2 min and incubation for 20 min at 97uCi n1 0m M
sodium citrate (pH 6.0). Sections were incubated with 5% goat
serum for 30 min, and subsequently with primary antibodies
(ATRX D-19) at a dilution of 1:50 overnight at 4uC. Secondary
goat antibodies were used to recognize the primary antibodies.
After washing, the horseradish peroxidase (HRP) conjugated
polymer complex was visualized by incubation for 2 to 10 min
with 3,30-diaminobenzidine (DAB) substrate-chromogen. Sections
were counterstained with methyl green, washed and mounted.
All images were taken at room temperature with a Retiga EX
camera (Leeds Precision Instruments, Inc.) connected to a
DMRA2 microscope (Leica). Image analysis was performed using
Openlab 4.0.4 software (Improvision).
Growth plate morphology was analyzed by Safranin-O stain on
P0.5 and P21 long bone sections. Sections were dewaxed, stained
in hematoxylin followed by staining in fast green and safranin-O.
Proportions of resting, proliferating and hypertrophic cells were
determined using Openlab 4.0.4 software (Improvision) from at
least three different mice.
Immunofluorescence of cultured primary chondrocytes.
Primary chondrocytes were prepared from long bones of E15.5
mouse embryos[33]. Briefly, long bones were dissected, rinsed in
PBS and incubated at 37uC for 20 min in trypsin-EDTA followed
by digestion with 2 mg/ml collagenase P at 37uC for 2 h in
Dulbecco’s Modified Eagles Medium (DMEM) with 10% FBS. The
cell suspension was filtered through a 70 mm cell strainer (Falcon),
washed, counted and plated. For ATRX immunofluorescence, cells
were grown on glass coverslips and fixed for 15 minutes in 4%
paraformaldehyde, then blocked with 5% goat serum for 30 min at
room temperature. Cells were then incubated with ATRX antibody
at a 1:300 dilution (H-300, Santa Cruz) and mouse anti-alpha
tubulin at a 1:10,000 dilution (Sigma) followed by FITC-conjugated
anti-rabbit and Alexa 594-conjugated anti-mouse secondary
antibodies. Slides were mounted in media containing DAPI and
images were acquired on a Leica DMI 6000 b automated inverted
microscope.
Mouse breeding and genotyping
Ethics Statement. All procedures involving animals were
approved by the University of Western Ontario Animal Care and
Use Committee.
Mice were exposed to a 12-hour light–dark cycle and fed tap
water and regular chow ad libitum. Mice conditionally deficient in
ATRX were generated by crossing of Atrx
LoxP females (129 sv
background) [6] with heterozygous Col2a1Cre–knock-in male mice
[22]. For developmental studies, midday of the day of vaginal plug
discovery was considered E0.5. At scheduled times pregnant
females were sacrificed by CO2.
PCR genotyping was performed from ear biopsy DNA for the
presence of the Cre transgene as previously described [22].
Genotyping of embryonic and newborn mice was performed using
PCR of DNA isolated from skin biopsies. PCR amplification was
performed to detect the Atrx floxed alleles as previously described
[8], the Cre transgene [22], as well as the sex determining region Y
(Sry) gene to identify male mice. A 1.5 kb fragment of neo gene
within the floxed allele of Atrx was identified with one set of
primers (59-GATCGGCCATTGAACAAGAT-39 and 59-ATA
GGT CGG CGG TTC AT-39) whereas the other set (59-CCC
GAG TAT CTG GAA GAC AG-39 and 59-ATA GGT CGG
CGG TTC AT-39) amplified a 600 bp fragment of wild type.
Primers (59-CCT GGA AAA TGC TTC TGT CC-39) and (59-
CAG GGT GTT ATA AAC AAT CCC-39) amplified a 300 bp
fragment of the cre gene, whereas the other set (59-GCA GGT
GGA AAA GCC TTA CA-39) and (59-AAG CTT TGC TGG
TTT TG GA -39) amplified a 250 bp fragment of Sry. PCR
conditions were as follows: 95uC for 3 min (95uC for 30 s, 55uC
for 45 s, and 72uC for 1 min) 636, 72uC for 10 min for Cre and
Sry,9 5 uC for 3 min (95uC for 30 s, 55uC for 1 min, and 72uC for
5 min) 636, 72uC for 10 min for Atrx.
Skeletal stains and measurements
LivemicewereweighedatP0,P7andP21.Wholebodylengthwas
measured using a ruler after sacrifice. For Alizarin Red/Alcian Blue
staining, mouse carcasses were skinned and eviscerated, then fixed
overnight in 95% ethanol followed by overnight fixation in acetone.
Whole skeletons were placed in staining solution for 7–10 days
(0.05% Alizarin Red, 0.015% Alcian Blue, 5% acetic acid in 70%
ethanol)[32]. Skeletons were then cleared in 2% KOH. Images of
stained bones were obtained with an Olympus SP-57OUZ. Limb
ATRX Function in Cartilage
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using a dissecting microscope with a ruler.
RT-PCR
Five micrograms of total RNA obtained from Atrx
Col2cre and
littermate control chondrocytes and control brains was reverse-
transcribed using Omniscript RT kit (Qiagen) and used for PCR
amplification with the following Atrx-specific primers: 17F (59 –
AGA ACC GTT AGT GCA GGT TCA-39) for exon 17 and 20a
(59-ACC ACC ATC TTC TTG CCA TC -39) for exon 20.
Conditions for amplification were as follows: 95uC for 3 min (95uC
for 30 s, 56uC for 30 s, and 72uC for 1 min) 6 32, 72uC for
10 min.
Western blot analysis
Primary rib cartilage was isolated from newborn mice. Ribs
were dissociated using collagenase P and strained through a 70mm
nylon filter to remove ossified tissue, followed by 3 days in culture
over 1.5% agarose in PBS to specifically select for chondrocytes
[34]. All tissues were lysed with MITO buffer (20 mM HEPES
pH 7.5, 1 mM EDTA pH 8.0, 10 mM KCl, 1.5 mM MgCl2 and
1 protease inhibitor cocktail tablet [Complete mini, EDTA-free;
Roche]), followed by treatment and lysis of nuclei with nuclear
buffers without and with salt, respectively (20 mM HEPES
pH 7.9, 450 mM NaCl (omitted for no salt) 1.5 mM MgCl2,
0.2 mM EDTA pH 8.0 and 1 protease inhibitor cocktail tablet).
Nuclear buffer without salt was used for swelling nuclei, nuclear
buffer with salt used for 25 minute nuclear lysis on ice. Extracts
were quantified using the BCA protein assay (Sigma-Aldrich).
Protein (5 mg) was resolved on a 6 % SDS-PAGE and transferred
onto nitrocellulose membranes (Bio-Rad Laboratories). The
membranes were probed with rabbit a-ATRX H300 (Santa Cruz
Biotechnology, Inc.) followed by the appropriate horseradish
peroxidase–conjugated secondary antibody (1:5,000; GE Health-
care). After washing, the membrane was incubated in ECL before
exposure using a ChemiImager 5500 (Alpha Innotech). The
membrane was reprobed with mouse anti–beta-actin (1:10,000;
Sigma-Aldrich) as a loading control.
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